L&K Biomed Hosts Academic Seminar with US Spine Specialists... Strengthening Collaboration on Next-Generation Products and New Growth Engines

L&K Biomed, a company specializing in spinal implants, announced on July 13 that it held the 'L&K Academic Seminar' from July 8 to 10, inviting leading spinal specialists from the United States to discuss the latest spinal treatment technologies and the direction of next-generation product development.

This seminar was attended by about 30 medical professionals and stakeholders, including Dr. Michael D. Burdi and Dr. Terrence T. Crowder—both of whom actively use L&K Biomed products in the United States—as well as Professor Yoon Doheum of Bundang CHA Hospital’s Department of Neurosurgery and Director Jeon Hyungjoon of Gwangmyeong 21st Century Hospital from Korea. The participants shared surgical techniques and clinical experiences from both Korea and the US, and engaged in in-depth discussions on next-generation spinal implant technology and future research and development directions.

In particular, Dr. Burdi, a spine specialist at Community Orthopedic Medical Group in California, actively performs minimally invasive surgeries using L&K Biomed’s flagship expandable cage, PathLoc-TM. At this seminar, the company introduced the clinical applicability and technological competitiveness of its new cervical expandable cage, BluEX-C, further strengthening the foundation for collaboration to expand into the US market.

Additionally, with Dr. Crowder, a spine specialist practicing in Arizona, the discussions focused on next-generation spinal treatment technologies and new product development, especially in the field of sacroiliac joint (SI) disorder treatment. Through this, the company concretized its product development strategy for the SI field, which it is nurturing as a future growth engine, and established a global research and development (R&D) collaboration base to strengthen its next-generation product lineup.

At the academic seminar held at Gwangmyeong 21st Century Hospital, Director Jeon Hyungjoon presented clinical cases and surgical experiences using L&K Biomed’s TLIF (Transforaminal Lumbar Interbody Fusion)-specific expandable cage. Dr. Burdi followed by introducing cases of minimally invasive spinal fusion and the clinical application of expandable cages performed at US ambulatory surgery centers (ASC). Dr. Crowder shared the latest treatment strategies and diverse clinical cases for SI disorders, enabling Korean and American medical professionals to exchange the latest treatment techniques and clinical experience.

Dr. Burdi stated, “Not only L&K Biomed’s existing products, but also BluEX-C, are highly differentiated in terms of technological strengths and are expected to be competitive enough to gain recognition among US healthcare professionals.” Dr. Crowder added, “Close collaboration between global healthcare professionals is essential for developing next-generation spinal treatment technologies, including in the SI field. I hope to contribute to the development of new treatment solutions through continuous R&D cooperation.”

An L&K Biomed representative commented, “This academic seminar was a meaningful opportunity to share the latest treatment techniques and clinical experience with international medical professionals, as well as to reaffirm the global competitiveness of our flagship products, next-generation product development, and future growth potential. Especially, as we have established a clinical collaboration base with US medical professionals centered around BluEX-C, we expect product adoption and market entry into major medical institutions in the western US to accelerate.”

Meanwhile, BluEX-C, L&K Biomed’s cervical expandable cage, recently completed its first clinical surgery in the US successfully and has been featured in leading spinal specialty media, marking an official start to targeting the local market. Since the first procedure, surgeries utilizing BluEX-C have been performed in succession, receiving high satisfaction from the field, and its adoption in actual clinical settings is rapidly expanding. The company plans to continue publicly sharing surgical reference results going forward.

This academic seminar served as a catalyst to further expand clinical cooperation with US healthcare professionals, strengthen the foundation for the development of next-generation products and the SI field as a future growth engine, and accelerate the company’s entry into the global spinal implant market.

This content was produced with the assistance of AI translation services.